1.32
price up icon3.13%   0.04
after-market Handel nachbörslich: 1.35 0.03 +2.27%
loading

Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten

pulisher
09:31 AM

Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

09:31 AM
pulisher
08:16 AM

HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat

08:16 AM
pulisher
02:52 AM

HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World

02:52 AM
pulisher
Apr 01, 2025

Galectin Therapeutics (NASDAQ:GALT) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

Galectin Therapeutics Reports Promising 2024 Results - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 21, 2025

Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com

Mar 21, 2025
pulisher
Mar 14, 2025

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail

Mar 14, 2025
pulisher
Mar 08, 2025

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance

Mar 08, 2025
pulisher
Mar 07, 2025

Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks

Mar 05, 2025
pulisher
Feb 26, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor - MSN

Feb 26, 2025
pulisher
Feb 20, 2025

Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta - Defense World

Feb 20, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics’ belapectin shows reduction in new varices - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Reports 68% Reduction In New Varices With Belapectin In NAVIGATE Trial U.S. Cohort - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics IncReports Significant Reduction In New Varices With Belapectin - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com South Africa

Feb 18, 2025
pulisher
Feb 18, 2025

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Major Breakthrough: Galectin's MASH Treatment Cuts Liver Complications by 68% in Latest Trial Data - StockTitan

Feb 18, 2025
pulisher
Feb 15, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Stratos Wealth Partners LTD. - Defense World

Feb 15, 2025
pulisher
Feb 04, 2025

Largest borrow rate increases among liquid names - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

JPMorgan Chase & Co. Grows Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Feb 04, 2025
pulisher
Jan 30, 2025

Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - The Malaysian Reserve

Jan 30, 2025
pulisher
Jan 29, 2025

Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR

Jan 29, 2025
pulisher
Jan 29, 2025

Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Galectin drops as trial for lead asset fails in MASH - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria

Jan 28, 2025
pulisher
Jan 25, 2025

Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jan 25, 2025
pulisher
Jan 23, 2025

Galectin Therapeutics Unveils Promising NAVIGATE Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 21, 2025

HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN

Jan 21, 2025
pulisher
Jan 18, 2025

Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

SouthState Corporation Announces Sale Agreement with Blue Owl Real Estate Capital On January 8, 2025, SouthState Bank, N.A., a subsidiary of SouthState Corporation, has entered into a significant agreement for the purchase and sale of real property w - Defense World

Jan 18, 2025
pulisher
Jan 15, 2025

Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire

Jan 15, 2025
pulisher
Jan 11, 2025

Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan

Jan 10, 2025
pulisher
Jan 10, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World

Jan 10, 2025
pulisher
Jan 08, 2025

Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Jan 08, 2025
pulisher
Jan 03, 2025

Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World

Jan 03, 2025
pulisher
Dec 31, 2024

Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria

Dec 31, 2024
pulisher
Dec 31, 2024

Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL

Dec 31, 2024
pulisher
Dec 31, 2024

Galectin Therapeutics (NASDAQ:GALT) Lowered to “Sell” Rating by StockNews.com - Defense World

Dec 31, 2024
pulisher
Dec 31, 2024

Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell" - MarketBeat

Dec 31, 2024
pulisher
Dec 30, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 41.1% in December - MarketBeat

Dec 30, 2024
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):